Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 3/20 | 0.64 |
| ▸ | CPA1 | P15085 | 2/20 | 0.64 |
| ▸ | CPB1 | P15086 | 1/20 | 0.64 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11460484 | 0.95 | CPA3 (0.64) | CPA3CPA1CPB1CPB2CYP1A2 | |
| SCHEMBL6176180 | 0.90 | CPA1 (0.55) | CPA3CPA1CPB1CPB2CYP1A2 | |
| SCHEMBL8051200 | 0.90 | CPA3 (0.58) | CPA3CPA1CPB1CPB2CYP1A2 | |
| SCHEMBL7297804 | 0.90 | CPA3 (0.58) | CPA3CPA1CPB1CPB2CYP1A2 | |
| SCHEMBL4168904 | 0.88 | CPA1 (0.56) | CPA3CPA1CPB1CPB2CYP1A2 | |
| SCHEMBL27694620 | 0.88 | CPA1 (0.56) | CPA3CPA1CPB1CPB2CYP1A2 | |
| SCHEMBL21121200 | 0.88 | CPA1 (0.56) | CPA3CPA1CPB1CPB2CYP1A2 | |
| SCHEMBL5233735 | 0.88 | CPA1 (0.56) | CPA3CPA1CPB1CPB2CYP1A2 | |
| SCHEMBL7332841 | 0.86 | CYP1A2 (0.56) | CPA3CPA1CPB1CPB2CYP1A2 | |
| SCHEMBL5177112 | 0.86 | CPA3 (0.61) | CPA3CPA1CPB1CPB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020141734-A1 | METHOD FOR PREPARING CHIRAL GAMMA-LACTAM COMPOUND AND METAL COMPLEX THEREFOR | 기초과학연구원 | 2020-07-09 | — | — | WO | disclosed |
| US-9950993-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-04-24 | — | — | US | disclosed |
| US-9950993-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160271081-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271081-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-22 | — | — | US | disclosed |
| EP-1203770-B1 | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hyperplasia and other diseases | UPJOHN CO (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-0668860-B1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | UPJOHN CO (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1203770-A1 | Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hyperplasia and other diseases | PHARMACIA & UPJOHN COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-0668860-A1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | PHARMACIA & UPJOHN COMPANY (US) | 1995-08-30 | — | — | EP | disclosed |
| WO-1994011361-A1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | THE UPJOHN COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271081-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | CPA3 3771/4885CPA1 2516/4885CPB1 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.